Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats


Cure M. C. , Cure E., Kalkan Y., Kirbas A., Tumkaya L. , Yilmaz A., ...More

BALKAN MEDICAL JOURNAL, vol.33, no.5, pp.504-511, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 5
  • Publication Date: 2016
  • Doi Number: 10.5152/balkanmedj.2016.150576
  • Title of Journal : BALKAN MEDICAL JOURNAL
  • Page Numbers: pp.504-511

Abstract

Background: Cisplatin (Cis) is one of the most commonly used antineoplastic drugs. It is used as chemotherapy for many solid organ malignancies such as brain, neck, male and female urogenital, vesical and pulmonary cancers. Infliximab blocks tumor necrosis factor alpha (TNF-alpha). Several studies have reported that infliximab ameliorates cell damage by reducing cytokine levels.